IFNA1 and hepatocellular carcinoma: Because of the deficient IFN-response found in our hepatoma panel, the enhanced cytotoxic effects of the epi-virotherapeutic combination approach can therefore not be attributed to the IFN-response (immuno-)modulating effects of resminostat.